Therefore, as shown in Figure 5B, we presumed that during the treatment of TLR9 agonist CpG ODNs on human lung cancer cells, TLR9 signaling induced the expression of HuR via PIK3/Akt pathway. The gene discussed is AKT1; the disease is lung carcinoma.